Oragenics, Inc. (OGEN) News
Follow Oragenics, Inc. (OGEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OGEN - Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
OGEN - Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
NEWS | Sep 16, 2026, 12:30 PM UTC
L
Oragenics discloses failure to satisfy continued listing rule
Oragenics disclosed a failure to satisfy a continued listing rule or standard.
EQUITY | Aug 28, 2026, 09:14 PM UTC
L
Oragenics review continues; plans for an IND by end-2026
Oragenics says it is reviewing certain items and remains focused on submitting an Investigational New Drug Application by the end of 2026.
EQUITY | Aug 28, 2026, 08:31 PM UTC
L
OGEN - Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
OGEN - Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
EQUITY | Aug 28, 2026, 08:31 PM UTC
M
Oragenics receives NYSE American deficiency notice
Oragenics (OGEN) received a deficiency letter from NYSE American LLC stating it is not in compliance with continued listing standards.
EQUITY | Aug 28, 2026, 08:31 PM UTC
L
Oragenics receives FDA responses on Type B meeting briefing
Oragenics received responses from the FDA related to its Type B meeting request briefing package submitted in July.
REGULATION | Aug 28, 2026, 08:31 PM UTC
L
Oragenics advances ONP-002 through Phase IIa feasibility trial in Australia
Oragenics says it is continuing to advance ONP-002, its lead intranasal mTBI candidate, through a Phase IIa feasibility trial in Australia.
EQUITY | Aug 28, 2026, 08:31 PM UTC
H
Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients
() -- Oragenics (OGEN) said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients. The biotech firm s
EARNINGS | Jul 07, 2026, 01:07 PM UTC